Influenza News and Research

Latest Influenza News and Research

Dietary supplements are effective and low-cost means to fight COVID-19

Supplements containing vitamins C and D and other micronutrients, sometimes in amounts exceeding the federally recommended levels, are a safe, effective and low-cost means of helping your immune system fight off COVID-19 and other acute respiratory tract diseases, an Oregon State University researcher says.

24 Apr 2020

First COVID-19-related clinical trial to start in Germany

German regulators have approved the first clinical trial of a coronavirus vaccine. Developed by BioNTech SE, an immunotherapy company, and Pfizer, a pharmaceutical company, the potential coronavirus vaccine has completed pre-clinical studies in Germany.

24 Apr 2020

U.S. may have to spend hundreds of billions treating COVID-19

A new study published in the journal Health Affairs in April 2020 quantifies the financial and resource burden which could be placed on the U.S. healthcare system at varying levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) community spread.

23 Apr 2020

Link between BCG and lower COVID-19 mortality disproved by new analysis

The association between BCG (Bacillus Calmette-Guérin) vaccination and its purported beneficial effect on COVID-19 transmission/mortality rates was challenged in an expert appraisal of Diamond Princess cruise ship data. At the same time, cross-national differences previously reported were shown to be flawed, reports a new medRxiv study.

23 Apr 2020

Biden says OSHA isn’t doing enough to protect workers’ from COVID-19

During an April 15 virtual town hall meeting with front-line workers, former Vice President Joe Biden, the Democrats' presumptive nominee for the White House, was asked by a meat processing worker what he would do to protect workers like her from COVID-19.

23 Apr 2020

Anti-SARS-CoV-2 / COVID-19 antibody: In stock and new formats

In mid-March, we announced the availability of an anti-coronavirus antibody shown to recognize SARS-CoV-2 (also referred to as 2019-nCoV or COVID-19). The anti-SARS clone, CR3022, was first described in 2006, and in early 2020, researchers showed the clone has high affinity for the then-termed 2019-nCoV. Scientists worldwide are now exploring this antibody as a candidate for mono- as well as combination-therapy development.

From Absolute Antibody Ltd 23 Apr 2020

Genomic sequencing shows COVID-19 spread patterns

Throughout the spread of the virus, genomic sequencing has played a role in epidemiologic tracking of the viral strains carried all over the world. Such strains are traced back to their origin by their unique mutations and help to link remote infections.

22 Apr 2020

Emergex partners with George Mason University for highly pathogenic RNA virus studies

Emergex Vaccines Holding Limited, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.

22 Apr 2020

Online searches predict daily incidence, deaths due to COVID-19 in US

The pandemic COVID-19 has affected more than 825,000 people in the US, but the daily number of new cases and deaths is not precise. A new study published on the preprint server medRxiv in April 2020 reports that Internet search interest could be used as a means to predict the daily incidence of cases in the US, as was proved in China.

21 Apr 2020

PiCoVacc vaccine candidate for COVID-19 effective in animal trials

In a new study available on the bioRxiv preprint server, a group of researchers from China report on the pilot-scale production of a purified inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus vaccine candidate (PiCoVacc), shown to induce virus-specific neutralizing antibodies in rats, mice, and non-human primates.

21 Apr 2020

Researchers develop new 3D multicomponent dissolvable vaccine platform

In parallel to their current work on a potential coronavirus vaccine, researchers at the University of Pittsburgh School of Medicine have developed a new vaccine delivery system for vaccines using live or attenuated viral vectors: a finger-tip sized patch that contains 400 tiny needles, each just half of one millimeter.

21 Apr 2020

Difference between flu and novel coronavirus disease

Both influenza and COVID-19 disease are caused by infectious respiratory agents and cause symptoms that can look quite similar. Coronaviruses cause both. So, what’s the difference?

21 Apr 2020

A promising method to diagnose sepsis with high accuracy

Whether activating or silencing genes, breaking down defective cells or building new tissue, our body is constantly working to repair itself, even in cases of illness.

21 Apr 2020

Sino Biological Partners with Nanommune Inc. to Develop and Market a Novel Coronavirus Multiplex Serological Assay

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology.

From Sino Biological Inc. 21 Apr 2020

The inside story of how the Bay Area got ahead of the COVID-19 crisis

Sunday was supposed to be a rare day off for Dr. Tomás Aragón after weeks of working around-the-clock.

21 Apr 2020

How Hong Kong reduced COVID-19 transmission

Amid the coronavirus disease (COVID-19) pandemic, many countries across the globe have imposed lockdowns in an attempt to reduce the spread of the virus. Still, some countries have not opted for lockdowns, and community quarantines, and still are doing well. Hong Kong, for one, appears to have averted a major COVID-19 outbreak despite not imposing lockdown.

21 Apr 2020

COVID-19 and immunodeficiency

COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.

21 Apr 2020

Does high COVID-19 viral load mean more risk of infection?

The risk of getting infected with COVID-19 disease is higher among healthcare workers who are in close contact with infected patients

21 Apr 2020

ACE2 receptor expression by SARS-CoV-2 across different animal species

A new report published on the preprint server bioRxiv in April 2020 reports that several species of animals can be infected with relative ease by the SARS-CoV-2 virus that is the causative agent of the currently raging COVID-19 pandemic. This casts much light on the possible natural hosts and routes of transmission of this virus.

20 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020